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ABSTRACT
Objectives: This study aimed to investigate what
percentage of National Institute for Health Research
(NIHR) Health Technology Assessment (HTA)
Programme-funded projects have published their final
reports in the programme’s journal HTA and to explore
reasons for non-publication.
Design: Retrospective cohort study.
Setting: Failure to publish findings from research is a
significant area of research waste. It has previously
been suggested that potentially over 50% of studies
funded are never published.
Participants: All NIHR HTA projects with a planned
submission date for their final report for publication in the
journal series on or before 9 December 2011 were
included.
Primary and secondary outcome measures: The
projects were classified according to the type of research,
whether they had been published or not; if not yet
published, whether they would be published in the future
or not. The reasons for non-publication were investigated.
Results: 628 projects were included: 582 (92.7%) had
published a monograph; 19 (3%) were expected to
publish a monograph; 13 (2.1%) were discontinued
studies and would not publish; 12 (1.9%) submitted a
report which did not lead to a publication as a
monograph; and two (0.3%) did not submit a report.
Overall, 95.7% of HTA studies either have published or
will publish a monograph: 94% for those commissioned
in 2002 or before and 98% for those commissioned after
2002. Of the 27 projects for which there will be no report,
the majority (21) were commissioned in 2002 or before.
Reasons why projects failed to complete included failure
to recruit; issues concerning the organisation where the
research was taking place; drug licensing issues; staffing
issues; and access to data.
Conclusions: The percentage of HTA projects for which
a monograph is published is high. The advantages of
funding organisations requiring publication in their own
journal include avoidance of publication bias and
research waste.
INTRODUCTION
It was stated by Chalmers and Glasziou1 that
worldwide over US$100 billion is invested
per year in biomedical research. They went
on to describe four stages at which waste of
this resource may occur: choosing the wrong
questions for research; doing studies that are
unnecessary or poorly designed; failure to
publish promptly or not at all; and biased or
unusable reports of research. This project
responds primarily to the third stage of
research waste identiﬁed, enabling accessible
full publication. In their paper, Chalmers
and Glasziou1 suggested that potentially over
50% of clinical trials funded are never pub-
lished in full. These data were obtained from
a Cochrane review2 which stated that “Less
than half of all studies, and about 60% of
randomized or controlled clinical trials, ini-
tially presented as summaries or abstracts at
professional meetings are subsequently pub-
lished as peer-reviewed journal articles.”
It is vitally important that studies report
in order to provide evidence to clinicians
to inform practice, and policy makers to
support them in decision-making. There is
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currently a move towards an open access to the data
from publically funded research3 4 in order to increase
the returns on public investment; to increase transpar-
ency; to prevent duplication in research commissioning;
to allow public scrutiny of the research process and
inform patient and public decision-making; and to make
the results of trials available to the public including par-
ticipants who have given their time to the study for
public beneﬁt.
It was also noted by Chalmers and Glasziou1 that pub-
lication bias leads to a systematic under-reporting of
studies with disappointing results, and that public access
to the full results of all research remains an aspiration.
Other investigators have also found lower publication
rates for studies with negative results or indeﬁnite con-
clusions.2 5–8 The National Institute for Health Research
(NIHR) Health Technology Assessment (HTA)
Programme commissions and funds primary research
and evidence synthesis on the effectiveness, costs and
broader impact of healthcare treatments and tests for
those who plan, provide or receive care in the National
Health Service (NHS). It aspires to maximise the return
on investment by enabling, where possible, all funded
projects to complete and publish and maximising the
impact for the money spent.9
The HTA Programme publishes a journal (HTA,
known colloquially as the monograph series) which is
available to all via the web and aims to publish a report
for each project funded. The monograph is unique
in that each publication focuses exclusively the ﬁnal
report of one study. Not only is publication encouraged
but also the agreement for the team to write and submit
this ﬁnal report is written into the contractual arrange-
ment at the time of funding. The report is typically
much longer than peer-reviewed journal articles as
teams are expected to publish full details of the studies
(such as a full description of the intervention)—essen-
tially as an archive of the study (irrespective of whether
the results are positive, negative or indeﬁnite), without
limits on word count or length, in a high impact factor
journal which is publically and freely available. Authors
are also encouraged to publish elsewhere to broaden
the dissemination of their ﬁndings, and there are other
processes for the dissemination of Technology
Assessment Reports (TARs). This project aims to investi-
gate the performance of the HTA Programme by asses-
sing what percentage of HTA projects are published in
the monograph series, and if they are not published
what are the reasons?
METHODS
For this study, we selected a cohort of HTA projects for
which the planned date for submission of their draft
ﬁnal report (DFR) for monograph publication was on
or before 9 December 2011. We identiﬁed these projects
from a proprietary database system used to manage the
HTA and other NIHR research programmes.
We excluded from the sample projects for which the
reports were supplementing monographs that were already
published; projects that were prospectively not considered
suitable for the publication of a monograph, for example,
working papers for the National Institute for health and
Clinical Excellence (NICE) or short brieﬁng papers; and
projects for which certain criteria needed to be met before
the project commences, for example, projects relating to
possible future H1N1 pandemics.
To assure data quality, NIHR Evaluation, Trials and
Studies Coordinating Centre staff with responsibility for
the publication process independently checked the
records for studies where there was no publication.
Similarly, where data indicated that no DFR had been
received, this information was again checked with the
team which should have received it.
All projects were categorised as either primary
research (typically randomised controlled trials); second-
ary research (mainly systematic reviews); HTA TARs
(which identify, assess and synthesise research evidence
from a number of healthcare interventions, providing
estimates of relative effectiveness and cost effectiveness
of a range of interventions) or NICE TARs (similar to
HTA TARs but prepared speciﬁcally for NICE). Projects
were also categorised as (1) Projects for which a mono-
graph has been published; (2) projects for which the
DFR had been received, but as yet there was no pub-
lished monograph; (3) No DFR received; and
(4) project discontinued. The data were further subdi-
vided into those projects where the commissioning
process started within the last 10 years (ie, after 2002),
and those where it began in 2002 or before.
When projects are published in the monograph series,
the DFRs go through an editorial review process which
is conducted between the editors, reviewers and authors.
Reports are published in the HTA journal series if they
are of a sufﬁciently high scientiﬁc quality as assessed by
the referees and editors.10 For projects which had not
been published yet, we needed to know whether a
report would eventually be produced. Projects in this
category were considered by a staff member (LT) with
experience in editorial processes, detailed knowledge of
the projects concerned and knowledge of editorial deci-
sions. They designated projects as either ‘will publish’ or
‘will not publish’. This judgement was made using the
following criteria. If at the end of the editorial process
the editorial board of the HTA journal had deemed the
report to be of ‘insufﬁcient quality’ to publish, this
report was recorded as ‘will not publish’. If a report has
been deemed as of sufﬁcient quality to publish this was
recorded as ‘will publish’. Data for ‘published’, ‘will
publish’ or ‘will not publish’ were originally obtained in
July 2012 and updated on 8 March 2013. Each project
was counted as one entity and the data were analysed by
the calculation of percentages.
For projects which were not expected to be published
(or had been discontinued, or where no DFR had been
received), we further investigated the reasons by
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interrogating in-house electronic records and by refer-
ring to hard copy project ﬁles which contained detailed
records of correspondence with the authors, at the time
when the report was due. For projects where no DFR
had been received, a web search (searching Medline via
Ovid, and Google Scholar; using authors’ names and
key words) and a search of internal records were con-
ducted to see if the results of the studies had been pub-
lished elsewhere.
RESULTS
Initial searches identiﬁed 642 projects (see ﬁgure 1). Of
these, one was excluded because it was a supplementary
project following a monograph which had already been
published; three because they related to potential future
H1N1 ﬂu pandemics and required particular circum-
stances to occur before the project would begin; one as
the report had been superseded by another; ﬁve as they
had been included with another report under a differ-
ent identiﬁcation number. Four projects were not suit-
able for publication as monographs as they were very
small and not suitable for publication alone; they had
been commissioned to report by a different route; or
were working papers for NICE. This left a cohort with a
ﬁnal total of 628 projects (201 primary research, 169 sys-
tematic reviews, 110 HTATARs and 148 NICE TARs).
For 31 projects, a DFR had been received, but as yet
there was no publication. After consultation with staff
expert in this area, it was deemed that 19 of these would
Figure 1 Flow diagram of projects included in study.
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eventually be published and 12 would not (see table 1).
By March 2013, all of the 19 reports expected to be pub-
lished were with the publisher and had been assigned
dates by which it was anticipated that they would be
published.
In total, 582 projects had published a monograph, two
studies had no DFR and 13 studies had been discontin-
ued (see table 2). For primary research studies, the
reasons for discontinuation were mainly failure to recruit;
for example, in one case, it was due to difﬁculties for the
principal investigator (PI) caused by reorganisation
within NHS institutions. For the systematic reviews and
TARs, the reasons were either to do with drug licensing
(NICE often requests TARs anticipating drug licensing,
to inform future guidance; if subsequently the drug is not
licensed, there is no need for a review, and NICE will
cancel its request consequently there will be no publica-
tion). Other reasons for discontinuation of the studies
were reliance being placed on access to data being
allowed by a third party who then would not release
the data; issues around key staff leaving; or being unwell.
A summary of results is given in table 2.
It was noticeable from the data that the majority of
projects that did not publish were those commissioned
early on in the history of the HTA Programme. The data
show that the vast majority of projects for which there
will be no publication in the HTA monograph series
were commissioned in 2002 or before (see ﬁgure 2).
There is a difference over time, where the percentage of
projects that are published rises from 94% to 98% and
the numbers of projects not completing or not publish-
ing fall from 6% to 2% after 2002.
More than half of the projects which will not be pub-
lished (6 of the 10 primary research studies and 1 of the
2 systematic reviews), and both projects that did not
submit a DFR were commissioned in 1993. This was
before the HTA Programme had the current processes
and procedures in place which have developed as the
programme matured. The results of the investigations,
as to why no monograph was to be published for pro-
jects for which a DFR had been submitted, are shown in
table 3. In the majority of cases (75%), this was because
the draft report was of insufﬁcient quality to be pub-
lished as a monograph. Currently, the HTA Programme
operates the editorial processes which work together
with authors to bring reports up to a publishable quality.
For one project commissioned in 1993, we were unable
to locate the paper ﬁles and so were unable to deter-
mine the reasons for non-publication. Most of the pro-
jects (83%) which were not published as monographs
were primary research projects.
Considering the two projects where no DFR had been
received, searches identiﬁed one peer-reviewed paper.
Eight of the primary research studies, where the DFRs
were received, were of insufﬁcient quality to be pub-
lished as monographs; ﬁve of these projects had also
been published elsewhere in peer-reviewed journals.
Whether or not a DFR is deemed to be of ‘insufﬁcient
quality’ to be published is a judgement made by the edi-
torial board of the HTA journal series. A monograph is
expected to cover all the aspects of the study concerned
in detail (average word count approx. 50 000 words); in
contrast, journal articles are much shorter (approxi-
mately 3000 words), less detailed and cover only certain
aspects of the study. The judgment concerning whether
a pilot study can be published as a ‘stand alone’ mono-
graph or possibly together with another study as a com-
bined monograph is made by the editorial board.
DISCUSSION
Overall, the percentage of projects commissioned by the
HTA Programme which are published in its journal is
Table 1 DFR received, not yet published: ‘will publish’ or
‘will not publish’
Type of research
Will
publish
Will not
publish
Total number
for which DFR
received but
not yet
published
Primary research 9 10 19
Systematic reviews 2 2 4
HTA TARs 4 0 4
NICE TARs 4 0 4
TOTALS 19 12 31
DFR, draft final report; HTA, Health Technology Assessment;
NICE, National Institute for health and Clinical Excellence;
TAR, Technology Assessment Report.
Table 2 Numbers of studies published and research type
PR SR HTA TAR NICE TAR Totals
Published 172 163 105 142 582 (92.7%)
No DFR received 2 0 0 0 2 (0.3%)
Discontinued studies 8 2 1 2 13 (2.1%)
DFR received—will publish 9 2 4 4 19 (3.0%)
DRF received—will not publish 10 2 0 0 12 (1.9%)
Totals 201 169 110 148 628 (100%)
DFR, draft final report; HTA, Health Technology Assessment; NICE, National Institute for health and Clinical Excellence; TAR, Technology
Assessment Report.
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high, for those commissioned in 2002 or before 94% is
published; for those commissioned after 2002, the ﬁgure
rises to 98%. This number is well in excess of the ﬁgure
of 50% quoted by Chalmers and Glasziou1 although it
must be born in mind that their data related to studies
initially presented as summaries or abstracts at profes-
sional meetings (which may include pilot or feasibility
studies which do not progress to full studies), rather than
commissioned projects, and so are likely to overestimate
the publication rate. This rate is also higher than some
other funders, for the National Institutes of Health in the
USA, after a median of 51 months after trial completion,
a third of trials remained unpublished.11
The strengths of this study were that it considered a
large sample of projects from a major UK research
funder, over a period of 18 years, encompassing a variety
of research methodologies. Additionally, in depth data
were available on most of the projects to enable us to
understand the reasons behind the statistical evidence.
Weaknesses include primary research projects consid-
ered within the cohort all related to a certain stage in
health research and had to be within the remit of the
HTA Programme which typically funds late-phase clinical
trials, investigating the effectiveness and cost effective-
ness of a diverse range of health technologies (which
may include drugs, devices, physical therapies, talking
therapies, public health interventions, surgical proce-
dures, etc). Consequently, the studies from earlier phase
trials were not represented in this study. This work does
not speciﬁcally consider the length of time to publica-
tion which is also pertinent12; however, this question is
being addressed in another study currently underway.
It is highly desirable that projects should publish the
ﬁnal results for the completed studies and the data pre-
sented here demonstrate a high level of project comple-
tion and publication. This is likely to be attributable to
three particular elements of the programme: (1) selec-
tion of the right projects at the beginning using a ‘needs
led’ process to identify research questions of the most
pressing interest to clinicians in the NHS. This also
encourages buy-in from investigators and participants
who are committed to answering important questions.
(2) A robust monitoring process which assists with
timely delivery, budgets, etc; and which can anticipate
which projects might fail and help to correct problems
as they arise. The majority of projects which have not
been published or will not be published were commis-
sioned very early in the history of the HTA Programme.
Current monitoring processes carefully monitor progress
of projects, and action is taken to assist the studies
Figure 2 Percentages of
projects commissioned either in
2002 or before or after 2002,
which do or do not publish in the
HTA monograph series.
Table 3 Reasons why no monograph is to be published for projects for which a DFR had been submitted
Draft final report
(DFR) of insufficient
quality
Study was only a pilot and
was not therefore published
as a monograph
Project commissioned in
1993, no records available Totals
Primary research 8 (67%) 2 (17%) 0 10 (83%)
Systematic reviews 1 (8%) 0 1 (8%) 2 (17%)
Totals 9 (75%) 2 (17%) 1 (8%) 12
DFR, draft final report.
Turner S, Wright D, Maeso R, et al. BMJ Open 2013;3:e002521. doi:10.1136/bmjopen-2012-002521 5
Publication rate for funded studies from a major UK health research funder
 group.bmj.com on August 20, 2014 - Published by bmjopen.bmj.comDownloaded from 
struggling with problems such as recruitment. It is likely
that the current processes of the HTA Programme for
both commissioning and monitoring have had a positive
effect on the monograph publication rate.
Element (3) is the existence of the HTA journal. The
high publication rate—a proxy for converting research
funding into useful and accessible knowledge—demon-
strates the beneﬁts of such a system. The teams are
offered not only the opportunity but also the space to
publish studies in full; it is part of the contractual
arrangement for funding and a proportion of funds is
with-held until the report has been received. The
journal publishes almost all projects regardless of results,
thus minimising publication bias. Authors are also
encouraged to publish in other peer-reviewed journals
to increase dissemination; however, the shorter length of
these articles does not allow for the reporting of the
detail presented in the monographs, for example,
detailed descriptions of the intervention. Some studies
elect to publish interim results in peer-reviewed journals;
however, it has been noted that the direction of effects
reported in interim analyses and subsequent ﬁnal ana-
lyses can vary,8 13 the monograph series publishes ﬁnal
results in full. Teams associated with projects for which
no monograph is to be published are strongly encour-
aged by the HTA Programme to publish in other jour-
nals. Of the two projects for which no DFR was
submitted, one had published a peer-reviewed paper else-
where; of the eight primary studies for which no mono-
graph was to be published, ﬁve had published
peer-reviewed papers elsewhere. This would indicate that
potential waste of resource had been minimised as at
least some of the ﬁndings had been disseminated. The
generalisability of these ﬁndings would only relate dir-
ectly to another funding system with an in-house journal,
but the general principles of encouraging and facilitating
publication would be generalisable to all funders.
Interesting areas for future research could be to
compare the ﬁndings of this study which has used data
from the HTA Programme with data from other funding
streams or organisations, both within the UK and inter-
nationally. Additionally, an investigation of the dissemin-
ation proﬁle of HTA projects in terms of journal
publications and publically accessible reports would be
informative.
Recommendations for future commissioning would
include funders making it a requirement for funded
projects to publish reports of ﬁnal ﬁndings, and for the
funders to facilitate this process.
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